July 22 (Reuters) - Life sciences firm Danaher ( DHR )

raised its annual profit forecast on Tuesday, banking on steady

demand for bioprocessing from its pharmaceutical clients and a

recovery in China.

Danaher ( DHR ), which provides tools and technologies that help

pharmaceutical companies develop and make drugs, said demand

from the industry remains strong, with robust number of clinical

trials and therapies under development.

CEO Rainer Blair said that patents expiring soon for several

high-volume therapies is also driving demand. Danaher ( DHR ) expects

high single-digit long-term growth for its bioprocessing unit.

"Monoclonal antibodies, which comprise more than 75% of our

bioprocessing revenues remain the largest investment area for

our customers," Blair said.

Revenues in China, about 12% of total sales, remained

pressured due to Chinese government policies such as

volume-based procurement and reimbursement changes.

But the company said its China business, barring

diagnostics, is improving, as government stimulus boosts pharma

and biotech industries.

Danaher's ( DHR ) current exposure to proposed tariffs stands at

"a couple hundred million dollars," down from previous

estimates, a company executive told analysts on a call.

Still, Danaher ( DHR ) flagged that demand from academic and

government sectors remained soft due to

uncertainty around research funding

, while clinical diagnostics and applied markets stayed

stable.

Evercore analyst Vijay Kumar said Danaher ( DHR ) has delivered a

"steady print" of results, and that improving trends in China

and a potential bioprocessing recovery in 2026 could boost

growth.

The company now forecasts annual adjusted profit per share

of $7.70 to $7.80, up from its previous projection of $7.60 to

$7.75.

Danaher ( DHR ) expects third-quarter revenue to rise at a

low-single-digit rate from a year earlier.

Second-quarter sales came in at $5.94 billion, surpassing

analysts' estimates of $5.84 billion, according to data compiled

by LSEG.

Separately, Danaher ( DHR ) announced that Matthew Gugino will be

succeeding long-time CFO Matthew McGrew, effective February 28,

2026.